{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:14:51Z","timestamp":1788585291168,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011772","name":"Novartis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jcjo.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:00:44Z","timestamp":1779249644000},"page":"1215-1225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vascular endothelial growth factor inhibitors outcomes in good vision eyes with neovascular age-related macular degeneration: Fight Retinal Blindness! SPAIN Report 4"],"prefix":"10.1016","volume":"61","author":[{"given":"Laura","family":"S\u00e1nchez-Vela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8755-0923","authenticated-orcid":false,"given":"Helena","family":"Brosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Martin-Pinardel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5469-3963","authenticated-orcid":false,"given":"Carolina","family":"Bernal-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0182-7950","authenticated-orcid":false,"given":"Alba","family":"Parrado-Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Moll-Udina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5048-4846","authenticated-orcid":false,"given":"Mart\u00edn","family":"Puzo-Bayod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5255-8426","authenticated-orcid":false,"given":"Gonzaga","family":"Garay-Aramburu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5312-8900","authenticated-orcid":false,"given":"Carolina","family":"Arruabarrena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sararols-Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Calvo-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0096-4569","authenticated-orcid":false,"given":"Miguel Angel","family":"Zapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5144-7334","authenticated-orcid":false,"given":"Marta","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximino","family":"Abraldes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9636-0788","authenticated-orcid":false,"given":"Jos\u00e9 Mar\u00eda","family":"Ruiz-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2990-0910","authenticated-orcid":false,"given":"Laura","family":"Broc-Iturralde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vel\u00e1zquez-Villoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Juan","family":"Escobar-Barranco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gallego-Pinazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta S.","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Garc\u00eda-Layana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-0539","authenticated-orcid":false,"given":"Marc","family":"Figueras-Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8580-0274","authenticated-orcid":false,"given":"Mark C.","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1812-9323","authenticated-orcid":false,"given":"Ricardo P.","family":"Casaroli-Marano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2338-8143","authenticated-orcid":false,"given":"Javier","family":"Zarranz-Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2026.04.001_bib0001","doi-asserted-by":"crossref","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. 2006;355:1419\u201331.","DOI":"10.1056\/NEJMoa054481"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0002","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"315","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0003","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Schmidt-Erfurth","year":"2014","journal-title":"Brit J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0004","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/jamaophthalmol.2019.5540","article-title":"Efficacy of a treat-and-extend regimen with ranibizumab in patients with neovascular age-related macular disease: a randomized clinical trial","volume":"138","author":"Kertes","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0005","doi-asserted-by":"crossref","first-page":"e820","DOI":"10.1111\/aos.14399","article-title":"Bimonthly, treat-and-extend and as-needed ranibizumab in na\u00efve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study","volume":"98","author":"L\u00f3pez G\u00e1lvez","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0006","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors","volume":"65","author":"Mehta","year":"2018","journal-title":"Progr Ret Eye Res"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0007","first-page":"1092","article-title":"The neovascular age-related macular degeneration database: Multicenter study of 92 976 ranibizumab injections: Report 1: Visual acuity manuscript no. 2013-568","volume":"121","author":"Tufail","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0008","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/bjophthalmol-2014-306229","article-title":"UK AMD EMR Users Group Report V: Benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6\/12","volume":"99","author":"Lee","year":"2015","journal-title":"Brit J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0009","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.ophtha.2014.04.026","article-title":"The neovascular age-related macular degeneration database: Report 2: Incidence, management, and visual outcomes of second treated eyes","volume":"121","author":"Zarranz-Ventura","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0010","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/bjophthalmol-2013-303233","article-title":"Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK","volume":"97","author":"Keenan","year":"2013","journal-title":"Brit J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0011","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2147\/OPTH.S256009","article-title":"Correlation of baseline visual acuity with outcomes of treatment with anti-VEGF in neovascular age-related macular degeneration","volume":"14","author":"Veluswamy","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0012","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1001\/jamaophthalmol.2016.5314","article-title":"The potential importance of detection of neovascular age-related macular degeneration when visual acuity is relatively good","volume":"135","author":"Ho","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0013","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000368249","article-title":"Intravitreal ranibizumab for patients with neovascular age-related macular degeneration with good baseline visual acuity","volume":"233","author":"Kato","year":"2015","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0014","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/eye.2011.224","article-title":"Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6\/12","volume":"25","author":"Williams","year":"2011","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0015","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/ceo.14054","article-title":"Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes","volume":"50","author":"Zarranz-Ventura","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0016","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1038\/s41433-024-03322-8","article-title":"Fight retinal blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study","volume":"38","author":"Puzo","year":"2024","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.jcjo.2026.04.001_bib0017","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/IAE.0b013e318296b271","article-title":"Efficient capture of high-quality data on outcomes of treatment for macular diseases: the Fight Retinal Blindness! project","volume":"34","author":"Gillies","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001038","article-title":"Associations with visual acuity outcomes after 12 months of treatment in 9401 eyes with neovascular AMD","volume":"7","author":"Relton","year":"2022","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0019","first-page":"56","article-title":"Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?","volume":"27","author":"Ross","year":"2013","journal-title":"Eye (Basingstoke)"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0020","first-page":"5","article-title":"Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision","volume":"39","author":"Shona","year":"2011","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0021","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.survophthal.2005.02.007","article-title":"Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment","volume":"50","author":"Slakter","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0022","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2007.08.012","article-title":"Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results","volume":"144","author":"Kaiser","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0023","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ophtha.2006.10.045","article-title":"Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration","volume":"114","author":"Boyer","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0024","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamaophthalmol.2014.109","article-title":"VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy","volume":"132","author":"Hagstrom","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.001_bib0025","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000841822600147X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000841822600147X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:25:56Z","timestamp":1788582356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000841822600147X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S000841822600147X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.04.001","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vascular endothelial growth factor inhibitors outcomes in good vision eyes with neovascular age-related macular degeneration: Fight Retinal Blindness! SPAIN Report 4","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}